We evaluated the effects of haemodilution with either dextran 40 or 0.9% normal saline on coagulation in vitro using rotational thromboelastometry (ROTEM®, Pentapharm Co., Munich, Germany) and multiple electrode aggregometry (Multiplate® Platelet Function Analyser, Dynabyte, Munich, Germany). Venous blood samples obtained from 20 healthy volunteers were diluted in vitro with dextran 40 or normal saline by 5%, 10% and 15%. Fibrinogen concentration, ROTEM-EXTEM® (screening test for the extrinsic coagulation pathway), FIBTEM® (an EXTEM-based assay of the fibrin component of clot) parameters including coagulation time, clot formation time, alpha angle, maximum clot firmness and lysis index were measured in the undiluted sample and at each level of haemodilution. Dextran 40 at 15% haemodilution significantly prolonged coagulation time, clot formation time and significantly decreased the alpha angle and maximal clot firmness (EXTEM amplitude at five minutes [A5] and ten minutes [A10]) compared with normal saline. The FIBTEM assay (maximal clot firmness and FIBTEM A5 and A10) showed a marked decrease in maximal clot firmness at all dilutions suggesting impaired fibrinogen activity and a risk of bleeding. Multiple electrode aggregometry did not demonstrate any platelet dysfunction. Haemodilution with dextran 40 causes significant impairment in clot formation and strength compared to saline haemodilution and undiluted blood. At the levels of in vitro haemodilution designed to reflect the clinical use of dextran infusions, no significant fibrinolysis or platelet inhibition was observed.
Recently, dextran 40 has been advocated to reduce the risk of embolic stroke during the endovascular management of cerebral aneurysms 1 . Dextran 40 (D40) is used in vascular and reconstructive plastic surgical procedures for its antithrombotic and anticoagulant properties [2] [3] [4] [5] [6] . It has also been reported that D40 reduces the frequency of postoperative deep vein thrombosis and pulmonary embolism 7 . The mechanisms of the antithrombotic actions of D40 are not well understood. Reductions in platelet adhesion 8 and aggregation [9] [10] [11] , and in Factor VIII 12 as well as impaired fibrin formation 13 have been reported.
The therapeutic value of D40 must be carefully weighed against its adverse effects such as allergy, renal failure and coagulopathy by dilution of plasma clotting factors as well as specific effects on certain plasma factors and cellular components. Prolonged bleeding time has been reported after the use of dextran 14 . The addition of dextran to local anaesthetic solutions reduces the systemic absorption of local anaesthetics and may prolong the duration of the block 15 . D40 is a major component of a solution used to dilute or wash thawed cord blood products used in stem cell transplants 16 .
The aim of this study was to evaluate the effects of serial in vitro haemodilution on coagulation utilising whole blood rotational thromboelastometry (ROTEM®, Pentapharm Co., Munich, Germany) and platelet function using multiple electrode aggregometry (MEA) (Multiplate® Platelet Function Analyser, Dynabyte, Munich, Germany).
Methods

After approval by the Sydney Local Health District Ethics
Review Committee (protocol number X14-0299; HREC/14/ RPAH/389), 20 healthy volunteers were recruited into the study with informed consent. The exclusion criteria included known coagulation disorders, major organ diseases, and the use of anticoagulant or non-steroidal anti-inflammatory drugs.
Blood sampling, baseline tests and haemodilution
Venous blood samples were obtained from upper forearm or antecubital fossa veins after application of a venous tourniquet. The Vacutainer® system (Becton Dickinson and Company, Franklin Lakes, NJ, USA) with a 21G needle was used and blood was sampled into tubes containing ethylenediaminetetraacetic acid, hirudin and four citrate tubes in that order. The ethylenediaminetetraacetic acid tube acts to exclude the first 4 ml of blood (prone to venepuncture-related coagulation activation) from subsequent coagulation evaluation.
The ethylenediaminetetraacetic acid and one citrate tube were delivered to our haematology laboratory to determine baseline coagulation status. Full blood count and fibrinogen level (measured in duplicate by the Clauss method) were obtained on all undiluted samples.
The venous blood samples in the citrate and hirudin tubes were diluted in fixed proportions by 1:19 (5%), 1:9 (10%) and 1:5.7 (15%) with either saline or D40. This range of dilutions was selected for its clinical relevance as it corresponded to in vivo haemodilution expected when D40 was infused at the recommended dose of up to 10 ml/kg/day. This equated to 700 ml of dextran for a subject weighing 70 kg, and with a blood volume of 70 ml/kg. Although higher doses (up to 20 ml/kg) of D40 have been recommended for volume replacement in acute shock, it is no longer used to treat shock.
Rotational thromboelastometry
Full blood and diluted samples were tested using ROTEM, which assesses the viscoelastic properties of clot formation, yielding information about the rate and strength of formed clots, as well as clot lysis. All the measurements were performed serially with the same ROTEM device in the same order, all within four hours in accordance with the manufacturer's recommendations (to avoid time-related coagulation changes). The EXTEM® assay assesses the extrinsic pathway of coagulation; 20 μl of star-tem® reagent (ROTEM, Pentapharm Co., Munich, Germany) containing 0.2 mol/l of calcium chloride, was added to 300 μl of citrated blood and then recombinant tissue factor (ROTEM, Pentapharm Co., Munich, Germany) was added to activate the extrinsic pathway.
FIBTEM® is an EXTEM-based assay used to assess the fibrin contribution to coagulation and is well correlated to the fibrinogen level determined by the gold standard Clauss method 17, 18 . Three hundred μl of citrated blood was mixed with 20 μl of star-tem reagent and 20 μl of cytochalasin dimethyl sulfoxide-d solution containing 0.2 mol/l calcium chloride (ROTEM, Pentapharm Co., Munich, Germany). Cytochalasin is a platelet inhibitor and the FIBTEM assay measures fibrin contribution to clotting. Coagulation parameters measured with EXTEM included clotting time (CT, time from start of run to 2 mm amplitude), clot formation time (CFT, time taken between 2 to 20 mm amplitude), alpha angle (angle of tangent to the curve at 2 mm point indicating clot formation rate), maximum clot firmness (MCF), amplitude of clot formation at five minutes (A5) 19, 20 , amplitude of clot formation at ten minutes (A10) 21 and lysis 30 index (percentage of clot remaining after 30 minutes). The CFT and alpha angle are not obtainable in the FIBTEM assay, but all other parameters are recorded as per EXTEM.
Multiple electrode aggregometry
Impedance aggregometry utilises the principle that activation of platelets results in platelet aggregation on artificial electrodes and this increases the electrical resistance between them; the change in resistance is recorded continuously. The MEA, based on impedance aggregometry, is used to assess platelet response to specific agonists in whole blood at the point of care 21 . We measured MEA response to four agonists. Adenosine diphosphate, thrombin receptor activating peptide, collagen and ristocetin were used to assess different pathways of platelet activation. Platelet aggregation was initiated by the addition of the following reagents: adenosine diphosphate test, adenosine diphosphate 0.2 mM; thrombin receptor activating peptide test, thrombin receptor activating peptide-6 1 mM; collagen test (COLtest), collagen 100 μg/ml; and ristocetin test (RISTOtest), ristocetin 0.2 mg/ml. The change in electrical impedance was measured as the area under the curve over six minutes.
Statistical analysis
Statistical analysis was performed using SPSS v20.0 software. Based on previous studies 22, 23 an estimated sample size of ten volunteers was required to provide a power of 80% at a 5% significance level to detect a 20% difference in ROTEM parameters. Multiple comparisons were performed using one-way analysis of variance, and a post hoc Tukey test was applied where a significant difference was detected. A P-value of <0.05 was considered statistically significant.
Results
Nine male and 11 female volunteers between the ages of 24 and 43 years were recruited. The baseline haemoglobin, platelet count, fibrinogen concentration, and thromboelastometric measurements were within normal limits.
EXTEM
The CT (which assesses activation of coagulation primarily by clotting factors) was prolonged by haemodilution with D40 compared with whole blood and this was significant at dilutions ≥10% (whole blood (WB) [78.1±9.5 seconds] versus 10% D40 dilution [93.3±11.4 seconds], P=0.002) (Figure 1 ). The CFT (which measures the rate of clot formation) was significantly prolonged with progressive haemodilution with dextran compared with WB at dilutions ≥10% (WB [101.4±21.4 seconds] versus 10% D40 dilution [146.7±24 seconds], P=0.0001) (Figure 2) . In contrast, the CT and CFT were not prolonged with saline haemodilution.
The EXTEM alpha angle (which assesses both rate and strength of clot formation) decreased with progressive haemodilution and this reached statistical significance with dextran at haemodilutions ≥5% (WB [69.7±3.6 degrees] versus 5% D40 dilution [65.4±3.6 degrees], P=0.001) (Figure 3 ).
The EXTEM MCF (which assesses the contribution of fibrinogen and platelets to clotting) was prolonged at all dextran dilutions (WB [6.5±3. 3 (Figure 4 ). Both the alpha angle and MCF were not significantly altered with saline. No significant clot lysis was observed at 30 minutes by haemodilution with either fluid.
FIBTEM
The CT was progressively prolonged by haemodilution with dextran and this was significant at 15% dilution (WB [68.4±7 seconds] versus 15% D40 dilution [203.6±2.5 seconds], P=0.001) but it was not changed with saline dilution ( Figure 5 ).
The FIBTEM MCF decreased significantly with all dilutions (WB [14.3±2.5 mm] versus 5% D40 dilution [9.5±2.1 mm], P=0.001) with dextran ( Figure 6 on next page). The MCF in the dextran group was also significantly lower than that with saline at each equivalent level of dilution.
The EXTEM and FIBTEM MCF A5 ( The contribution of platelets to clot strength was obtained in ROTEM by subtracting FIBTEM MCF from EXTEM MCF. There was no difference in platelet contribution to clot strength between the two study fluids.
Multiplate electrode aggregometry
There were no differences in area under the curve for the impedances measured in the adenosine diphosphate test, thrombin receptor activating peptide test, COLtest and RISTOtest between full blood and blood diluted with either normal saline or dextran at any level of dilution. There was no significant difference between the two fluids at all levels of dilution (Figure 7 ).
Discussion
This study demonstrated that even with mild haemodilution, D40 impaired clot formation and MCF in vitro when assessed with thromboelastometry. Significant coagulopathy may occur when the dose of D40 exceeds 10 ml/kg because the FIBTEM A5 and A10 parameters at this level of haemodilution indicate an increased risk of bleeding 19, 20 . In our study, the FIBTEM A5 and A10 parameters at 15% dilution with D40 were at the levels consistent with an increased risk of coagulopathy. The coagulation impairments were greater than that associated with haemodilution alone. Mortier et al 24 reported coagulation disturbances with profound (50%) haemodilution with a variety of fluids. We have shown that these coagulation defects can occur at much lower levels of haemodilution (10%) with D40. The FIBTEM findings in this study suggest that D40 infusions impaired fibrinogen activity at this low level of haemodilution. This supports the findings of Tsao and Krajewski 13 who, using scanning electron microscopy, demonstrated that dextran impaired the effect of polymerising fibrin in the stimulation of platelet aggregation and release reaction 13 . Although Jones et al 25 showed that D40 enhanced endogenous fibrinolysis in 20 patients undergoing endovascular stenting, we could not demonstrate fibrinolysis in this in vitro model. Previous studies demonstrated that fibrinogen concentration decreases proportionally with progressive in vitro haemodilution with intravenous fluids 23 .
Using MEA, we did not demonstrate impaired platelet receptor function when dextran was added to WB. However, Robless et al 26 , using WB flow cytometry and platelet aggregometry, showed that D40 inhibited platelets by reducing P-selectin (which mediates adhesion of activated platelets to monocytes and leukocytes) and PAC-1 (which binds to activated platelets and activates the fibrinogen binding site exposed by glycoprotein IIb-IIIa conformatiomal changes). D40 was shown to markedly reduce collageninduced platelet aggregation in an in vitro study in patients with peripheral arterial disease 26 . Factor VIII has been implicated in dextran-induced coagulopathy 27 but the activity of most other coagulation factors appear to not be significantly impaired even with high levels of in vitro dextran dilution 28 .
The fact that this study was done in vitro may be considered a major limitation. The study was performed under static conditions and did not assess the influence of shear forces on the interaction of coagulation factors and the endothelium 29 . Given the complexity of the coagulation system it may be difficult to extrapolate these in vitro changes to clinical (in vivo) situations.
A possible implication of our results for clinical practice is that the anticoagulant effects of D40 occur at low levels of haemodilution (around 10%) and caution should be undertaken when D40 is administered to patients for its antithrombotic properties in the perioperative setting. A slow infusion rate should be used and the total volume of D40 administered should not exceed 10% of the patient's blood volume to avoid excessive bleeding perioperatively.
